Avacta Group Plc (AVCTF)
USD 0.52
(0.0%)
USD 0.52
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.57 Million GBP | 4.56% |
| 2022 | 7.24 Million GBP | 259.1% |
| 2021 | 2.01 Million GBP | -7.52% |
| 2020 | 2.18 Million GBP | -32.22% |
| 2019 | 3.21 Million GBP | 72.09% |
| 2018 | 1.87 Million GBP | 4.24% |
| 2017 | 1.79 Million GBP | 41.26% |
| 2016 | 1.27 Million GBP | -1.32% |
| 2015 | 1.28 Million GBP | -36.88% |
| 2014 | 2.03 Million GBP | 34.77% |
| 2013 | 1.51 Million GBP | 0.13% |
| 2012 | 1.51 Million GBP | -38.2% |
| 2011 | 2.44 Million GBP | 18.29% |
| 2010 | 2.06 Million GBP | 118.96% |
| 2009 | 944 Thousand GBP | 102.58% |
| 2008 | 466 Thousand GBP | 119.81% |
| 2007 | 212 Thousand GBP | 6966.67% |
| 2006 | 3000.00 GBP | -96.63% |
| 2005 | 89 Thousand GBP | 568.42% |
| 2004 | -19 Thousand GBP | 0.0% |
| 2003 | - GBP | -100.0% |
| 2002 | 4000.00 GBP | -42.86% |
| 2001 | 7000.00 GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | 3.37 Million GBP | 1100.71% |
| 2023 Q2 | 5.03 Million GBP | 49.23% |
| 2023 FY | 7.57 Million GBP | 4.56% |
| 2023 Q4 | 2.53 Million GBP | 12.9% |
| 2023 Q3 | 2.24 Million GBP | -55.35% |
| 2022 Q2 | 3.95 Million GBP | 49.82% |
| 2022 Q3 | 665 Thousand GBP | -83.16% |
| 2022 FY | 7.24 Million GBP | 259.1% |
| 2022 Q1 | 2.63 Million GBP | 189.92% |
| 2022 Q4 | 281 Thousand GBP | -57.74% |
| 2021 Q3 | -753 Thousand GBP | -275.12% |
| 2021 Q2 | 430 Thousand GBP | 53.85% |
| 2021 Q4 | -2.93 Million GBP | -289.38% |
| 2021 Q1 | 279.5 Thousand GBP | 4092.86% |
| 2021 FY | 2.01 Million GBP | -7.52% |
| 2020 Q4 | -7000.00 GBP | -102.28% |
| 2020 Q1 | 280 Thousand GBP | 0.0% |
| 2020 Q2 | 34 Thousand GBP | -87.86% |
| 2020 FY | 2.18 Million GBP | -32.22% |
| 2020 Q3 | 307 Thousand GBP | 802.94% |
| 2019 Q2 | 1.27 Million GBP | 0.0% |
| 2019 FY | 3.21 Million GBP | 72.09% |
| 2019 Q1 | 1.27 Million GBP | 425.77% |
| 2018 Q1 | -63.5 Thousand GBP | -112.6% |
| 2018 FY | 1.87 Million GBP | 4.24% |
| 2018 Q4 | -392 Thousand GBP | 0.0% |
| 2018 Q2 | -250 Thousand GBP | -293.7% |
| 2017 Q2 | 456.5 Thousand GBP | 0.0% |
| 2017 Q4 | 504 Thousand GBP | 0.0% |
| 2017 FY | 1.79 Million GBP | 41.26% |
| 2017 Q1 | 456.5 Thousand GBP | 3.63% |
| 2017 Q3 | 504 Thousand GBP | 10.41% |
| 2016 Q2 | 330 Thousand GBP | 0.0% |
| 2016 FY | 1.27 Million GBP | -1.32% |
| 2016 Q3 | 440.5 Thousand GBP | 33.48% |
| 2016 Q4 | 440.5 Thousand GBP | 0.0% |
| 2016 Q1 | 330 Thousand GBP | 8.2% |
| 2015 Q4 | 305 Thousand GBP | 0.0% |
| 2015 FY | 1.28 Million GBP | -36.88% |
| 2015 Q3 | 305 Thousand GBP | -25.25% |
| 2015 Q2 | 408 Thousand GBP | 0.0% |
| 2015 Q1 | 408 Thousand GBP | 73.25% |
| 2014 Q2 | 272 Thousand GBP | 0.0% |
| 2014 Q1 | 272 Thousand GBP | -0.55% |
| 2014 Q4 | 235.5 Thousand GBP | 0.0% |
| 2014 FY | 2.03 Million GBP | 34.77% |
| 2014 Q3 | 235.5 Thousand GBP | -13.42% |
| 2013 FY | 1.51 Million GBP | 0.13% |
| 2013 Q2 | 437 Thousand GBP | 0.0% |
| 2013 Q3 | 273.5 Thousand GBP | -37.41% |
| 2013 Q4 | 273.5 Thousand GBP | 0.0% |
| 2013 Q1 | 437 Thousand GBP | 36.78% |
| 2012 Q4 | 319.5 Thousand GBP | 0.0% |
| 2012 FY | 1.51 Million GBP | -38.2% |
| 2012 Q3 | 319.5 Thousand GBP | 0.0% |
| 2011 FY | 2.44 Million GBP | 18.29% |
| 2010 FY | 2.06 Million GBP | 118.96% |
| 2009 FY | 944 Thousand GBP | 102.58% |
| 2008 FY | 466 Thousand GBP | 119.81% |
| 2007 FY | 212 Thousand GBP | 6966.67% |
| 2006 FY | 3000.00 GBP | -96.63% |
| 2005 FY | 89 Thousand GBP | 568.42% |
| 2004 FY | -19 Thousand GBP | 0.0% |
| 2003 FY | - GBP | -100.0% |
| 2002 FY | 4000.00 GBP | -42.86% |
| 2001 FY | 7000.00 GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 49.51% |
| SQZ Biotechnologies Company | 9.79 Million USD | 22.677% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -11421.726% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 35.307% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 93.642% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 22275.695% |
| Mesoblast Limited | -35.16 Million USD | 121.534% |
| Marizyme, Inc. | 457.7 Thousand USD | -1554.57% |
| Genus plc | 178.7 Million USD | 95.762% |
| Pharming Group N.V. | 220.1 Million USD | 96.559% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -12070.154% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1746.33% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 68945.455% |
| ContraFect Corporation | -154 Thousand USD | 5017.532% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -9765.687% |
| IMV Inc. | -962.29 Thousand USD | 886.97% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 2054.318% |
| MultiCell Technologies, Inc. | 49.32 USD | -15354725.629% |
| ONE Bio Corp. | 20.12 Million USD | 62.371% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 81.192% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 73.198% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 49198.807% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 763.383% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -10718.571% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 6194.921% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 153028.11% |
| Arch Therapeutics, Inc. | -2439.00 USD | 310596.105% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -5290.036% |
| GB Sciences, Inc. | -624.00 USD | 1213721.795% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 8902.948% |
| CSL Limited | 7.56 Billion USD | 99.9% |
| Agentix Corp. | - USD | -Infinity% |
| Enzolytics Inc. | 30.7 Thousand USD | -24561.326% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -1469.752% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.317% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 129.355% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 1571.886% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 98.151% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -244032.818% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 85612.647% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 9131.712% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 15246.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -666.513% |
| EV Biologics, Inc. | 48.9 Thousand USD | -15386.708% |
| Q BioMed Inc. | -8988.00 USD | 84356.787% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 21.205% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 82.927% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 50.904% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 7865.985% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 3640965.385% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 15792.41% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -4189.193% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -1126.627% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 1301.8% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 64088.171% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -4189.193% |
| Affymax, Inc. | 1.35 Million USD | -458.01% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 26213.793% |
| International Stem Cell Corporation | 4.6 Million USD | -64.345% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -8285.00 USD | 91506.156% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -1582.728% |
| SYBLEU INC | 11.69 Thousand USD | -64648.632% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 2470.214% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 2130.295% |
| Neutra Corp. | 14.33 Thousand USD | -52728.741% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 9335.366% |
| PureTech Health plc | -1.6 Million USD | 572.427% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 856.365% |
| IXICO plc | 3.27 Million USD | -131.59% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 1191.21% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 522.836% |
| CSL Limited | 7.7 Billion USD | 99.902% |
| Cellectis S.A. | 18 Thousand USD | -41972.222% |